Three hybrid assay system

• US 7,135,550 B2
• Filed: 09/03/2002
• Issued: 11/14/2006
• Est. Priority Date: 03/02/2001
• Status: Expired due to Fees

• Current Assignee: GPC Biotech Inc. (GPC AG - Genome Pharmaceuticals Corp.)
• Original Assignee: GPC Biotech AG (Agennix AG), GPC Biotech Inc. (GPC AG - Genome Pharmaceuticals Corp.)
• Inventors: Becker, Frank, Reichel, Christoph, Come, Jon H., Kley, Nikolai A.
• Primary Examiner(s): Ketter, James
• Application Number:
  US10/234,985
• Publication Number:
  US 20040043388A1
• Time in Patent Office: 1,533 Days
• Field of Search: 435/6, 530/350
• US Class Current: 530/350
• CPC Class Codes: C07D 231/54 condensed with carbocyclic rings or ring systems
• CPC Class Codes: C07D 487/04 Ortho-condensed systems
• CPC Class Codes: C07F 9/65583 each of the hetero rings containing nitrogen as ring hetero atom
• CPC Class Codes: C07F 9/6561 containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
• CPC Class Codes: C40B 30/04 by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
• CPC Class Codes: G01N 2500/10 involving cells
• CPC Class Codes: G01N 33/6845 Methods of identifying protein-protein interactions in protein mixtures

Abstract

The invention provides compositions and methods for isolating ligand binding polypeptides for a user-specified ligand, and for isolating small molecule ligands for a user-specified target polypeptide using an improved class of hybrid ligand compounds.

Claims

1. A hybrid ligand represented by the general formula:

R1-Y—

R2, wherein;

(i) R1 represents a first ligand selected from;

a steroid, retinoic acid, beta-lactam antibiotic, cannabinoid, nucleic acid, polypeptide, FK506, FK506 derivative, rapamycin, tetracycline, methotrexate, novobiocin, maltose, glutathione, biotin, vitamin D, dexamethasone, estrogen, progesterone, cortisone, testosterone, nickel, 2,4-diaminopteridine or cyclosporin, or a derivative thereof with structural modifications that retain a biological activity thereof;

(ii) Y represents a polyethylene linker having the general formula (CH₂—

X—

CH₂)_n, where X represents O, S, SO, or SO₂, and n is an integer from 2 to 25; and

,

(iii) R2 represents a user-specified second ligand different from R1 selected from;

a peptide, nucleic acid, carbohydrate, polysaccharide, lipid, prostaglandin, acyl halide, alcohol, aldehyde, alkane, alkene, alkyne, alkyl, alkyl halide, alkaloid, amine, aromatic hydrocarbon, sulfonate ester, carboxylate acid, aryl halide, ester, phenol, ether, nitrile, carboxylic acid anhydride, amide, quaternary ammonium salt, imine, enamine, amine oxide, cyanohydrin, organocadmium, aldol, organometallic, aromatic hydrocarbon, nucleoside, or a nucleotide.

2. The hybrid ligand of claim 1, wherein the first ligand binds to a polypeptide.

3. The hybrid ligand of claim 2, wherein the binding affinity corresponds to a ligand/polypeptide dissociation constant K_D of less than 1 μ

M.

4. The hybrid ligand of claim 2, wherein the first ligand is capable of forming a covalent bond with the polypeptide.

5. The hybrid ligand of claim 1, wherein X is O.

6. The hybrid ligand of claim 1, wherein Y is (CH₂—

O—

CH₂)_n, where n=2 to 5.

7. The hybrid ligand of claim 1, wherein R1 is dexamethasone.

8. The hybrid ligand of claim 1, wherein R1 is methotrexate, a methotrexate derivative, FK506, an FK506 derivative or a 2,4-diaminopteridine derivative.

9. The hybrid ligand of claim 1, wherein R1 is methotrexate and Y is (CH₂—

O—

CH₂)_n, where n=2 to 5.

10. The hybrid ligand of claim 1, wherein R2 is a ligand selected from:

a compound with a known biological effect, a compound with an unknown mechanism of action, a compound which binds to more than one polypeptide, a drug candidate compound, or a compound that binds to an unknown protein.

11. The hybrid ligand of claim 1, wherein R2 binds to or inhibits a kinase.

12. A hybrid ligand represented by the general formula:

R1-Y—

R2, wherein;

(i) R1 represents a first ligand selected from;

a steroid, retinoic acid, beta-lactam antibiotic, cannabinoid, nucleic acid, polypeptide, FK506, FK506 derivative, rapamycin, tetracycline, methotrexate, novobiocin, maltose, glutathione, biotin, vitamin D, dexamethasone, estrogen, progesterone, cortisone, testosterone, nickel, or 2,4-diaminopteridine or cyclosporin, or a derivative thereof with structural modifications that retain a biological activity thereof;

(ii) Y represents a linker; and

,

(iii) R2 represents a user-specified second ligand different from R1 selected from;

a peptide, nucleic acid, carbohydrate, polysaccharide, lipid, prostaglandin, acyl halide, alcohol, aldehyde, alkane, alkene, alkyne, alkyl, alkyl halide, alkaloid, amine, aromatic hydrocarbon, sulfonate ester, carboxylate acid, aryl halide, ester, phenol, ether, nitrile, carboxylic acid anhydride, amide, quaternary ammonium salt, imine, enamine, amine oxide, cyanohydrin, organocadmium, aldol, organometallic, aromatic hydrocarbon, nucleoside, or a nucleotide;

wherein R2 binds to or inhibits a kinase.

13. The hybrid ligand of claim 12, wherein the kinase is a cyclin dependent kinase.

14. The hybrid ligand of claim 12, wherein R2 is a ligand selected from Table 2, or a derivative thereof with structural modifications that retain a biological activity thereof.

15. The hybrid ligand of claim 12 wherein Y represents a polyethylene linker having the general formula (CH₂—

X—

CH₂)_n, where X represents O, S, SO, or SO₂, and n is an integer from 2 to 25.

16. A fusion polypeptide, comprising segments P1, Cub-Z, and RM, in an order wherein Cub-Z is closer to the N-terminus of the fusion polypeptide than RM, wherein

(i) P1 is a ligand binding polypeptide that binds to a non-peptide ligand of a hybrid ligand, which has the general formula R1-Y—

R2, where R1 and R2 are ligands, and Y is a linker,

(ii) Cub is a carboxy-terminal subdomain of ubiquitin,

(iii) Z is an amino acid residue,

(iv) RM is a reporter moiety.

18. The fusion polypeptide of claim 16 or 17, wherein the non-peptide ligands are:

a steroid, retinoic acid, beta-lactam antibiotic, cannabinoid, nucleic acid, FK506, FK506 derivative, rapamycin, tetracycline, methotrexate, 2,4-diaminopteridine derivative, novobiocin, maltose, glutathione, biotin, vitamin D, dexamethasone, estrogen, progesterone, cortisone, testosterone, nickel, cyclosporin, or a derivative thereof with structural modifications that retain a biological activity thereof;

or a carbohydrate, polysaccharide, lipid, prostaglandin, acyl halide, alcohol, aldehyde, alkane, alkene, alkyne, alkyl, alkyl halide, alkaloid, amine, aromatic hydrocarbon, sulfonate ester, carboxylate acid, aryl halide, ester, phenol, ether, nitrile, carboxylic acid anhydride, amide, quaternary ammonium salt, imine, enamine, amine oxide, cyanohydrin, organocadmium, aldol, organometallic, aromatic hydrocarbon, nucleoside, or a nucleotide.

19. The fusion polypeptide of claim 16, wherein Z is a non-methionine amino acid.

20. The fusion polypeptide of claim 16, wherein RM is:

a polypeptide capable of emitting light upon excitation, a polypeptide with an enzymatic activity, a detectable tag or a transcription factor.

21. The fusion polypeptide of claim 16, wherein RM is:

green fluorescent protein, URA3 or PLV.

22. A nucleic acid encoding the fusion polypeptide of any one of claims 16 or 17.

17. A fusion polypeptide, comprising segments P1 and Nux, wherein

(i) Nux is the amino-terminal subdomain of a wild-type ubiquitin or a reduced-associating mutant ubiquitin amino-terminal subdomain, and

(ii) P1 is a ligand binding polypeptide that binds to a non-peptide ligand of a hybrid ligand, which has the general formula R1-Y—

R2, where R1 and R2 are ligands, R1 is different from R2, and at least one of R1 and R2 is not a peptide, and Y is a linker.

23. A composition, comprising:

(i) a hybrid ligand of the general formula R1-Y—

R2, where R1 and R2 are ligands, R1 is different from R2 and at least one of R1 and R2 is not a peptide, Y is a linker; and

,

(ii) at least one of two fusion polypeptides comprising;

(a) a first fusion polypeptide comprising segments P2, Cub-Z, and RM, in an order wherein Cub-Z is closer to the N-terminus of the first fusion polypeptide than RM, wherein P2 is a ligand binding polypeptide that may bind to ligand R1 or R2 of the hybrid ligand, Cub is a carboxy-terminal subdomain of ubiquitin and RM is a reporter moiety, and Z is an amino acid residue;

(b) a second fusion polypeptide comprising segments Nux and P1, wherein Nux is the amino-terminal subdomain of a wild-type ubiquitin or a reduced-associating mutant ubiquitin amino-terminal subdomain, and P1 is a ligand binding polypeptide that may bind to ligand R1 or R2 of the hybrid ligand.

26. The composition of any one of claims 23 to 25, wherein the composition is a complex.

27. The composition of any one of claims 23 to 25, wherein the composition is provided in an environment chosen from:

a cell, a container, a kit, a solution or a growth medium.

24. A composition, comprising:

(i) a hybrid ligand represented by the general formula;

R1-Y—

R2, wherein;

(a) R1 represents a first ligand selected from;

a steroid, retinoic acid, beta-lactam antibiotic, cannabinoid, nucleic acid, polypeptide, FK506, FK506 derivative, rapamycin, tetracycline, methotrexate, 2,4-diaminopteridine derivative, novobiocin, maltose, glutathione, biotin, vitamin D, dexamethasone, estrogen, progesterone, cortisone, testosterone, nickel, or cyclosporin, or a derivative thereof with minor structural modifications that retain a biological activity thereof;

(b) Y represents a polyethylene linker having the general formula (CH₂—

X—

CH₂)_n, where X represents O, S, SO, or SO₂, and n is an integer from 2 to 25;

(c) R2 represents a user-specified second ligand different from R1 selected from;

a peptide, nucleic acid, carbohydrate, polysaccharide, lipid, prostaglandin, acyl halide, alcohol, aldehyde, alkane, alkene, alkyne, alkyl, alkyl halide, alkaloid, amine, aromatic hydrocarbon, sulfonate ester, carboxylate acid, aryl halide, ester, phenol, ether, nitrile, carboxylic acid anhydride, amide, quaternary ammonium salt, imine, enamine, amine oxide, cyanohydrin, organocadmium, aldol, organometallic, aromatic hydrocarbon, nucleoside, or a nucleotide;

(ii) at least one fusion polypeptide selected from;

(a) a first fusion polypeptide comprising;

a ligand binding domain P1 and a domain selected from the group consisting of;

a DNA binding domain and a transcriptional activation domain, wherein the ligand binding domain binds the first ligand R1; and

,

(b) a second fusion polypeptide comprising;

a candidate ligand-binding domain P2 for the user-specified ligand R2 and a domain selected from the group consisting of;

a DNA binding domain and a transcriptional activation domain.

wherein one of the first and second fusion polypeptides contains a DNA binding domain and the other fusion polypeptide contains a transcription activation domain.

25. A composition comprising:

(i) A hybrid ligand represented by the general formula;

R1-Y—

R2, wherein;

(a) R1 represents a first ligand selected from;

a steroid, retinoic acid, beta-lactam antibiotic, cannabinoid, nucleic acid, polypeptide, FK506, FK506 derivative, rapamycin, tetracycline, methotrexate, 2,4-diaminopteridine derivative, novobiocin, maltose, glutathione, biotin, vitamin D, dexamethasone, estrogen, progesterone, cortisone, testosterone, nickel, or cyclosporin or a derivative thereof with structural modifications that retain a biological activity thereof.

(b) Y represents a polyethylene linker having the general formula (CH₂—

X—

CH₂)_n, where X represents O, S, SO, or SO₂, and n is an integer from 2 to 25;

(c) R2 represents a user-specified second ligand different from R1 selected from;

a peptide, nucleic acid, carbohydrate, polysaccharide, lipid, prostaglandin, acyl halide, alcohol, aldehyde, alkane, alkene, alkyne, alkyl, alkyl halide, alkaloid, amine, aromatic hydrocarbon, sulfonate ester, carboxylate acid, aryl halide, ester, phenol, ether, nitrile, carboxylic acid anhydride, amide, quaternary ammonium salt, imine, enamine, amine oxide, cyanohydrin, organocadmium, aldol, organometallic, aromatic hydrocarbon, nucleoside, or a nucleotide; and

(ii) a fusion polypeptide that includes;

(a) at least one ligand binding domain; and

,

(b) a functional domain heterologous to the ligand binding domain which by itself is not capable of inducing or allowing the detection of a detectable event, but which is capable of inducing or allowing the detection of a detectable event when brought into proximity of a second functional domain.

28. A kit comprising:

(i) a compound of general structure R1-Y-L, wherein;

(a) Y is of the general structure (CH₂—

X—

CH₂)_n, wherein X represents O, S, SO, or SO₂, and n is an integer from 2 to 25;

(b) R1 is selected from;

steroid, retinoic acid, beta-lactam antibiotic, cannabinoid, nucleic acid, polypeptide, FK506, FK506 derivative, rapamycin, tetracycline, methotrexate, novobiocin, maltose, glutathione, biotin, vitamin D, dexamethasone, estrogen, progesterone, cortisone, testosterone, nickel, 2,4-diaminopteridine or cyclosporin, or a derivative thereof with structural modifications that retain a biological activity thereof, and,

(c) L is a chemical group that can be substituted by a different chemical group, and

(ii) instructions to use the compound for the synthesis of a hybrid ligand R1-Y—

R2 where R1 is different from R2, and at least one of R1 and R2 is not a peptide.

29. A composition comprising:

(i) a hybrid ligand of general structure R1-Y—

R2, wherein R1 represents a first ligand selected from;

steroid, retinoic acid, beta-lactam antibiotic, cannabinoid, nucleic acid, polypeptide, FK506, FK506 derivative, rapamycin, tetracycline, methotrexate, novobiocin, maltose, glutathione, biotin, vitamin D, dexamethasone, estrogen, progesterone, cortisone, testosterone, nickel, 2,4-diaminopteridine or cyclosporin, or a derivative thereof with structural modifications that retain a biological activity thereof;

Y is a linker having the general formula (CH₂—

X—

CH₂)₂; and

R2 represents a user-specified second ligand different from R1 selected from;

a peptide, nucleic acid, carbohydrate, polysaccharide, lipid, prostaglandin, acyl halide, alcohol, aldehyde, alkane, alkene, alkyne, alkyl, alkyl halide, alkaloid, amine, aromatic hydrocarbon, sulfonate ester, carboxylate acid, aryl halide, ester, phenol, ether, nitrile, carboxylic acid anhydride, amide, quaternary ammonium salt, imine, enamine, amine oxide, cyanohydrin, organocadmium, aldol, organometallic, aromatic hydrocarbon, nucleoside, or a nucleotide, and

(ii) a fusion polypeptide, comprising at least two domains which are not found in combination in nature, wherein

(a) one domain is a user specified polypeptide, and

(b) a second domain is a DNA binding domain.

30. The composition of claim 29, wherein n is an integer from 2 to 25.

31. The composition of claim 29, wherein X=O, S, SO or SO₂.

32. The composition of claim 29, wherein R1 represents a first ligand selected from:

a steroid, retinoic acid, beta-lactam antibiotic, cannabinoid, FK506, FK506 derivative, rapamycin, tetracycline, methotrexate, novobiocin, maltose, glutathione, vitamin D, dexamethasone, estrogen, progesterone, cortisone, testosterone, 2,4-diaminopteridine derivative or cyclosporin, or a derivative of one of the above with structural modifications that retain a biological activity thereof.

33. A composition comprising

(i) a polypeptide comprising a fragment of a β

-lactamase and a user specified polypeptide, and

(ii) a second polypeptide comprising a second fragment of a β

-lactamase and a domain chosen from the group consisting of;

β

-lactamase, a steroid receptor, retinoic acid receptor, cannabinoid receptor, FKB12, Tet-R, DHFR, GyrB, maltose binding protein, glutathione-S-transferase, vitamin D receptor, glucocorticoid receptor, estrogen receptor, progesterone receptor, testosterone receptor, or a fragment of one of the above, which fragment retains the binding capacity to its respective ligand,

wherein said first and second fragments of a β

-lactamase individually possess no β

-lactamase activity, and wherein the enzymatic activity of a β

-lactamase is reconstituted when P1 and P2 are brought into close spatial proximity.

34. The composition of claim 33, further comprising a hybrid ligand of general structure R1-Y—

R2, wherein Y is a linker.

35. The composition of claim 34, wherein Y is of the general structure (CH₂—

X—

CH₂)_n, and n is an integer from 2 to 25.

36. The composition of claim 35, wherein X=O, S, SO or SO₂.

37. The composition of claim 34, wherein R1 represents a first ligand selected from:

a steroid, retinoic acid, beta-lactam antibiotic, cannabinoid, nucleic acid, polypeptide, FK506, FK506 derivative, rapamycin, tetracycline, methotrexate, novobiocin, maltose, glutathione, biotin, vitamin D, dexamethasone, estrogen, progesterone, cortisone, testosterone, nickel, 2,4-diaminopteridine derivative or cyclosporin, or a derivative of one of the above with structural modifications that retain a biological activity thereof.